
    
      Inclusion Criteria： Age ≥ 50 y/o, nAMD patients（including PCV） Best-corrected visual
      acuity（BCVA） Exclusion Criteria： Previous anti-VEGF treatment within 3 months History of
      intraocular surgery within 3 months or arrangement of intraocular surgery in the next 6
      months from baseline Active or recent intraocular inflammation in the study eye Primary
      Endpoint： Improvement in BCVA compared to baseline Other： Central Macular Thickness after
      Treatment，Numbers of Injections
    
  